A cardiologist-focused view of how aggressive LDL-C goals translate into real-world treatment intensification, which nonstatin therapies are used first, where statin intolerance and access barriers slow progress, and why long-term control can weaken after an acute coronary event.
Audience: Cardiologists
Countries: 6
Completion Rate: 69%
SGID: 8953232
-Hero findings
– Quick Read — Key Findings
For cardiologists managing established ASCVD, the lipid conversation has shifted from whether LDL-C should be lowered aggressively to how reliably very-high-risk patients can reach and maintain the target in everyday practice.
For external context, the 2026 ACC/AHA guideline reintroduced explicit goals, recommending LDL-C below 55 mg/dL for very-high-risk patients and lipoprotein(a) measurement at least once in adulthood, while the 2025 ESC/EAS update reinforced early intensification, including during an acute coronary syndrome admission. These sharpen the target but not the operational work between identifying risk and sustaining treatment, which the MDForLives cardiology survey maps from the clinician’s view: target attainment, intensification triggers, first-line therapies, access barriers, intolerance handling, post-ACS drop-off, Lp(a) use, and the system change most likely to close the gap.
46.4% estimate that only 40%–59% of their very-high-risk ASCVD patients achieve LDL-C below 55 mg/dL.
Only 7.1% estimate at least 80% of very-high-risk patients reach the target, and 23.2% put it at 60%–79%, so control clusters in the partial-attainment middle even where the rationale for aggressive lowering is strongest. The shape of the distribution matters: most cardiologists are not describing a complete failure to lower LDL-C, but relatively few see consistent target attainment across most of their very-high-risk patients. This points to a gap between achieving some LDL-C reduction and reliably getting patients below the recommended threshold over time.
55.6% say LDL-C remaining above target despite maximally tolerated statin therapy is the most common reason to add or initiate a nonstatin agent.
Ezetimibe leads first add-ons at 41.5%, ahead of PCSK9 monoclonal antibodies (28.3%), bempedoic acid or combinations (17.0%), and inclisiran (11.3%); separately, 24.1% intensify on very high baseline risk and 11.1% on documented intolerance, so the trigger is not always the LDL-C number alone. The spread across first add-on choices also shows that escalation is not a single fixed sequence in practice. The same need for further LDL-C lowering can lead to different therapeutic routes depending on the amount of additional reduction required, treatment tolerance, and practical considerations around access and use.
34.0% identify strict step-therapy rules requiring failure of multiple statins and ezetimibe first as their single greatest administrative challenge.
Prior-authorization paperwork and denials follow at 24.5%, out-of-pocket costs at 17.0%, and specialty-pharmacy delays at 13.2%, while only 11.3% report no significant barrier, so nearly nine in ten hit friction that sits between the decision and the fill. The pattern is important because the leading obstacles appear after the need for treatment has already been recognized. In other words, the challenge is often operational rather than diagnostic: moving from an appropriate clinical decision to an approved, affordable, and dispensed therapy becomes a separate hurdle in secondary prevention.
38.5% first try a different statin, lower dose, or alternate-day regimen when a patient reports statin intolerance.
Another 23.1% move directly to nonstatin therapy, 21.2% first check biomarkers such as CK, vitamin D, or thyroid function, 13.5% counsel on safety and the nocebo effect, and 3.8% refer to a lipid clinic, so intolerance is worked as a pathway with rechallenge as the default rather than a stop. The distribution also shows that a report of intolerance does not produce one uniform response. Instead, cardiologists appear to use several routes to clarify tolerability, investigate other possible contributors to symptoms, and preserve effective lipid lowering before deciding how heavily to rely on nonstatin therapy.
28.8% identify PCP de-escalation or failure to intensify lipid therapy during routine visits as the greatest drop-off in long-term LDL-C control.
Patient self-discontinuation is nearly as common at 26.9%, with missed follow-up at 17.3%, payer or formulary changes at 15.4%, and no post-discharge panel within 4–12 weeks at 11.5%, so failure is spread across clinicians, patients, payers, and monitoring rather than one weak point. Because the leading causes occur at different stages of the post-discharge journey, the chart suggests that long-term control depends on continuity rather than any single visit. An aggressive inpatient plan can still lose momentum if responsibility for retesting, treatment intensification, affordability, and medication persistence becomes fragmented after discharge.
28.8% use Lp(a) selectively for strong family history or unexpected premature events, while 36.5% say automatic EHR alerts for unachieved LDL targets would have the highest impact on closing the LDL-C gap.
Routine Lp(a) testing for all high-risk patients is 25.0%, another 25.0% reserve it for residual-risk cases, and 21.2% rarely order it; on the system side EHR alerts lead, ahead of automated prior authorization (21.2%), broader coverage or lower copays (17.3%), lipid coordinators (17.3%), and patient education (7.7%). The split in Lp(a) use suggests that residual-risk assessment is not yet embedded uniformly across cardiology practice. At the same time, the preference for EHR alerts points to a workflow need: identifying patients who remain above LDL-C targets and prompting action at the right point in follow-up may be as important as adding more treatment options.
The survey describes a secondary-prevention environment where high-risk patients make up a large share of the panel and the threshold is clear, yet estimated goal attainment stays concentrated below universal control, and intensification, though usually triggered when LDL-C stays high, can be slowed by step therapy, prior authorization, cost, or specialty-pharmacy logistics.
Statin intolerance adds a layer, since the clinician must separate a modifiable dosing problem from true intolerance while avoiding prolonged high LDL-C, and after an acute coronary event responsibility becomes distributed, with the largest drop-offs involving de-intensification, patient discontinuation, missed follow-up, coverage changes, and delayed retesting.
Lp(a) screening and EHR alerts point the same way: risk information is most useful embedded in a reliable workflow, so closing the gap may require not one new therapy but a system that connects target recognition, escalation, access, monitoring, and persistence without losing the patient between steps.
You have read the summary
Common questions about LDL-C goals, nonstatin therapy, statin intolerance, Lp(a), and long-term ASCVD prevention.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
